Development and validation of an 18F-FDG PET/CT radiomic nomogram for predicting axillary lymph-node status after neoadjuvant chemotherapy for breast cancer: a multicenter study
Annals of Nuclear Medicine · 2025
DOI: 10.1007/s12149-025-02099-4 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Annals of Nuclear Medicine, 2025. Verfasst von Yu Li und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nuclear Medicine, Cancer Center, Zhejiang Provincial People's Hospital (Affiliated People's Hospital), Hangzhou Medical College, 158 Sh…. Hauptthemen laut MEDLINE: Breast Neoplasms, Positron Emission Tomography Computed Tomography, Fluorodeoxyglucose F18, Neoadjuvant Therapy. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Onkologische Pflege
Abstract (Originalsprache)
Rationale and objective To develop and validate the predictive value of 18 F-FDG PET/CT radiomics models based on data preprocessing methods for axillary lymph-node (ALN) status after neoadjuvant chemotherapy (NAC) for breast cancer. Materials and methods According to the status of ALN after NAC, we divided the breast cancer patients of the three scanners into the pathological complete remission (pCR) and non-pCR groups, respectively. Totally 630 models were obtained based on various data preprocessing, feature filtering, and modeling approaches. On the one hand, different data preprocessing methods were compared to analyze the advantages of different preprocessing methods. On the other hand, the AUC of predicting ALN status was compared among all models, and the model with the best prediction was obtained. Finally, the optimal model is combined with the clinical and the corresponding Nomogram is plotted.
Results
The comparison of the data preprocessing modalities revealed that the model prediction of tumor-to-liver ratio (TLR) radiomics was better than origin radiomics (OR), and the effect of Combat and Limma was better than without batch effects. All preprocessing modalities could be used as a potential method that can further optimize the model. The optimal model had a predicted AUC of 0.798 for ALN status after NAC for breast cancer in the test set and an AUC of 0.811 when combined with clinical characteristics.
Conclusion
It is necessary to pre-process the data before conducting a study on multicenter data, and the model developed in this way can effectively predict the status of ALN after NAC in breast cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Nuclear Medicine, Cancer Center, Zhejiang Provincial People's Hospital (Affiliated People's Hospital), Hangzhou Medical College, 158 Shangtang Road, Hangzhou, Zhejiang, China.
- Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, 310022, Zhejiang, China.
- Department of Nuclear Medicine, Cancer Center, Zhejiang Provincial People's Hospital (Affiliated People's Hospital), Hangzhou Medical College, 158 Shangtang Road, Hangzhou, Zhejiang, China. 1357056119@qq.com.
Zitieren
APA
Li, Y., Chen, K., Jin, L., & Huang, H. (2025). Development and validation of an 18F-FDG PET/CT radiomic nomogram for predicting axillary lymph-node status after neoadjuvant chemotherapy for breast cancer: a multicenter study. Annals of Nuclear Medicine. https://doi.org/10.1007/s12149-025-02099-4
Vancouver
Li Y, Chen K, Jin L, Huang H. Development and validation of an 18F-FDG PET/CT radiomic nomogram for predicting axillary lymph-node status after neoadjuvant chemotherapy for breast cancer: a multicenter study. Annals of Nuclear Medicine. 2025. doi:10.1007/s12149-025-02099-4
BibTeX
@article{Li2025,
author = {Li, Yu and Chen, Kun and Jin, Luqiang and Huang, Hailin},
title = {Development and validation of an 18F-FDG PET/CT radiomic nomogram for predicting axillary lymph-node status after neoadjuvant chemotherapy for breast cancer: a multicenter study},
journal = {Annals of Nuclear Medicine},
year = {2025},
doi = {10.1007/s12149-025-02099-4}
}
EUVIMED